Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to outsmart Hard-to-Treat cancers

NCT ID NCT06789172

Recruiting now Disease control Sponsor: Epkin Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, stomach, or sarcoma. About 146 participants will take part across the US, Australia, UK, and EU.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

OKN4395 (an experimental drug) and pembrolizumab (an immunotherapy)

What this could lead to

If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.

What could go wrong

This is an early Phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. The drug may cause side effects or fail to shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm dedifferentiated liposarcoma dermatofibrosarcoma protuberans gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma leiomyosarcoma liposarcoma myxofibrosarcoma non-small cell lung carcinoma pancreatic adenocarcinoma sarcoma solitary fibrous tumor Squamous Cell Carcinoma of Head and Neck undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER (CRC) DEDIFFERENTIATED LIPOSARCOMA GASTRIC CANCER (GC) GASTRIC CANCER ADENOCARCINOMA METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC LEIOMYOSARCOMA LEIOMYOSARCOMA (LMS) MYXOFIBROSARCOMA (MFS) NON-SMALL-CELL LUNG CANCER NSCLC PANCREATIC ADENOCARCINOMA SARCOMA SOLID TUMOURS SOLITARY FIBROUS TUMORS UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chris O'Brien Lifehouse

    RECRUITING

    Sydney, New South Wales, Australia

  • Churchill Hospital

    RECRUITING

    Oxford, United Kingdom

  • Leicester Royal Infirmary

    RECRUITING

    Leicester, LE1 5WW, United Kingdom

  • Linear Clinical Research

    RECRUITING

    Perth, Western Australia, 6009, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Precision NextGen Oncology and Research Center

    RECRUITING

    Beverly Hills, California, 90212, United States

    Contact Phone: •••-•••-••••

  • Sarcoma Oncology Center

    RECRUITING

    Santa Monica, California, 90403, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Beatson

    RECRUITING

    Glasgow, United Kingdom

  • The Christie

    RECRUITING

    Manchester, United Kingdom

  • University College London Hospital

    RECRUITING

    London, United Kingdom

    Contact Email: •••••@•••••